Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GAIL L WRIGHT

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1669432290
CMS profile
211190
Location
HUDSON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,234.24

77 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,169.24 76
Education $65.00 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GAIL L WRIGHT

NPI 1669432290 · CMS profile ID 211190

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

HUDSON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669432290?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GAIL L WRIGHT, NPI 1669432290, CMS profile ID 211190. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669432290?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). GAIL L WRIGHT, NPI 1669432290, CMS profile ID 211190. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669432290?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
GAIL L WRIGHT, NPI 1669432290, CMS profile ID 211190, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1669432290?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

77 matching records · $1,234.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 77 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–77 of 77.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $14.6904/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737175337 CMS
Novartis Pharmaceuticals Corporation $15.7203/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726198724 CMS
Janssen Biotech, Inc. $12.9303/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719145511 CMS
Veracyte, Inc. $0.5503/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 753806019 CMS
Novartis Pharmaceuticals Corporation $14.9502/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726198721 CMS
EMD Serono, Inc. $11.0002/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751269975 CMS
AstraZeneca Pharmaceuticals LP $14.1602/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736140751 CMS
Janssen Pharmaceuticals, Inc $12.1902/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719145509 CMS
Seagen Inc. $10.6602/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 732433925 CMS
AbbVie Inc. $21.1102/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722188327 CMS
PFIZER INC. $11.1202/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743517143 CMS
GlaxoSmithKline, LLC. $26.0502/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738520269 CMS
Genentech USA, Inc. $19.7902/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743015043 CMS
Novartis Pharmaceuticals Corporation $16.7802/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726198717 CMS
E.R. Squibb & Sons, L.L.C. $14.6702/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727957499 CMS
Celgene Corporation $13.4802/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727957570 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.1101/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720724787 CMS
Novartis Pharmaceuticals Corporation $18.9401/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726198715 CMS
Eisai Inc. $14.0401/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751203279 CMS
E.R. Squibb & Sons, L.L.C. $20.5201/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727957495 CMS
Eisai Inc. $21.3401/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751203277 CMS
Novartis Pharmaceuticals Corporation $21.3701/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726198711 CMS
Janssen Biotech, Inc. $11.5501/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719145513 CMS
Astellas Pharma US Inc $21.4701/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718399091 CMS
Bayer HealthCare Pharmaceuticals Inc. $15.6101/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713635477 CMS
Janssen Biotech, Inc. $11.5801/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719145515 CMS
Amgen Inc. $22.2801/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741046029 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,001.62 142
PY2020 $1,234.24 77
PY2021 $1,869.22 118
PY2022 $2,856.92 161
PY2023 $3,378.19 160
PY2024 $7,126.96 199
PY2025 $2,767.14 128

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,228,719.16 48
PY2024 Principal investigator $364,881.43 85
PY2023 Principal investigator $1,584,275.57 174
PY2022 Principal investigator $2,421,068.49 240
PY2021 Principal investigator $3,323,416.04 215
PY2020 Principal investigator $3,469,029.84 182
PY2019 Principal investigator $1,375,448.56 108

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,250.00 12/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228746863
Principal investigator 1 PFIZER INC. $631.80 11/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228724558
Principal investigator 1 Daiichi Sankyo Inc. $650.00 11/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378089
Principal investigator 1 Daiichi Sankyo Inc. $690.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378083
Principal investigator 1 Daiichi Sankyo Inc. $125.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378085
Principal investigator 1 Daiichi Sankyo Inc. $1,623.00 11/07/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378091
Principal investigator 1 Daiichi Sankyo Inc. $2,230.00 11/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378087
Principal investigator 1 PFIZER INC. $5,891.00 10/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228740893
Principal investigator 1 PFIZER INC. $775.00 10/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228756483
Principal investigator 1 PFIZER INC. $2,145.60 09/19/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228762040
Principal investigator 1 Daiichi Sankyo Inc. $5,278.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378077
Principal investigator 1 Daiichi Sankyo Inc. $650.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378079
Principal investigator 1 Daiichi Sankyo Inc. $5,733.00 09/03/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378081
Principal investigator 1 Genmab U.S., Inc. $51,505.07 08/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors No dispute reported 06/30/2026 1235934170
Principal investigator 1 PFIZER INC. $3,490.00 08/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228767723
Principal investigator 1 PFIZER INC. $1,250.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228765086
Principal investigator 1 PFIZER INC. $1,250.00 07/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228784024
Principal investigator 1 PFIZER INC. $1,000.00 07/11/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228773837
Principal investigator 1 Eli Lilly and Company $1,982.00 07/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1187887832
Principal investigator 1 Daiichi Sankyo Inc. $4,004.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378065
Principal investigator 1 Daiichi Sankyo Inc. $5,915.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378067
Principal investigator 1 Daiichi Sankyo Inc. $650.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378069
Principal investigator 1 Daiichi Sankyo Inc. $4,459.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378071
Principal investigator 1 Daiichi Sankyo Inc. $362.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378073
Principal investigator 1 Daiichi Sankyo Inc. $4,823.00 06/26/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute
DS8201-A-U302 No dispute reported 06/30/2026 1223378075
Principal investigator 1 GlaxoSmithKline, LLC. $334.00 06/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE-ATLANTA-UNITE
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1192171605
Principal investigator 1 PFIZER INC. $775.00 06/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228794016
Principal investigator 1 PFIZER INC. $1,250.00 06/09/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228793043
Principal investigator 1 AstraZeneca Pharmaceuticals LP $291,340.36 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185551038
Principal investigator 1 GlaxoSmithKline, LLC. $1,479.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE-ATLANTA-UNITE
A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFF No dispute reported 06/30/2026 1192171608
Principal investigator 1 PFIZER INC. $1,250.00 05/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228771534
Principal investigator 1 PFIZER INC. $5,327.80 05/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228772789
Principal investigator 1 AstraZeneca Pharmaceuticals LP $395,803.93 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185551042
Principal investigator 1 PFIZER INC. $775.00 04/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228796294
Principal investigator 1 PFIZER INC. $500.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228780585
Principal investigator 1 Eli Lilly and Company $8.40 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY No dispute reported 06/30/2026 1187882398
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,200.00 03/27/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
SOLAR1 A phase III randomized double blind placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive HER2 negative advanced breast cancer which progressed on or after aromatase in No dispute reported 06/30/2026 1190304453
Principal investigator 1 PFIZER INC. $9,197.80 03/22/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228788813
Principal investigator 1 PFIZER INC. $1,000.00 03/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228767003
Principal investigator 1 PFIZER INC. $1,250.00 03/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH TRASTUZUMAB AND PERTUZUMAB AS MAINTENANCE THERAPY FOR METASTATIC HER2 BREAST CANCER HER2CLIMB05 No dispute reported 06/30/2026 1228765566
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,354.71 02/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF DATO-DXD VERSUS INVESTIGATORS CHOICE OF CHEMOTHERAPY IN PARTICIPANTS WITH INOPERABLE OR METASTATIC HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE BEEN TREATED WITH ONE OR TWO PRIOR LINES OF SYSTEMIC CHEMOTHERAPY No dispute reported 06/30/2026 1185551040
Principal investigator 1 PFIZER INC. $1,250.00 02/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228797553
Principal investigator 1 PFIZER INC. $4,457.10 02/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228749759
Principal investigator 1 Novartis Pharmaceuticals Corporation $139,086.39 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190303223
Principal investigator 1 PFIZER INC. $1,500.00 01/15/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228724212
Principal investigator 1 PFIZER INC. $11,483.80 01/10/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228799031
Principal investigator 1 PFIZER INC. $1,250.00 01/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228723926
Principal investigator 1 AstraZeneca Pharmaceuticals LP $246,483.40 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185551036